Prostatype Genomics AB (publ) (STO:PROGEN)
Sweden · Delayed Price · Currency is SEK 0.0970
-0.0014 (-1.42%)
Aug 13, 2026, 5:20 PM CET
Prostatype Genomics AB Company Description
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests.
The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, RTqPCR kit, patient database and algorithms, Prostatype Web System (PWS), and tumor stage, as well as calculates the P-score.
Its test is based on a database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision.
The company was incorporated in 2007 and is headquartered in Nacka, Sweden.
Prostatype Genomics AB (publ)
| Country | Sweden |
| Founded | 2007 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Fredrik Rickman |
Contact Details
Address: Augustendalsvägen 20 Nacka, 131 52 Sweden | |
| Phone | 46 08 20 87 00 |
| Website | prostatypegenomics.com |
Stock Details
| Ticker Symbol | PROGEN |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0014684569 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Fredrik Rickman | Chief Executive Officer and MD |
| Anders Koch | Chief Financial Officer |
| George Skinner | Vice President Commercial operations |
| Emelie Berglund | Chief Technology Officer |
| Nicklas Rosendal | Communications Director |
| Joakim Soderin | Chief Auditor |
| Prof. Gerald L. Andriole Jr., M.D. | Global Chief Medical Officer |
| Katarina Sjöberg | Head of RA and QA |
| Steven Gaal | President of US operations |
| Mats Bergström | Sales Director of EMEA |